Dividend Stock Portfolio For Retirement

3. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 86

AbbVie Inc. (NYSE:ABBV) is included among the stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), for treating Hepatitis C.

The updated approval allows Mavyret—made from the antiviral agents glecaprevir and pibrentasvir—to be used in the US for both adults and children aged three and older with acute or chronic Hepatitis C, provided they do not have cirrhosis or have compensated cirrhosis. Eligible patients can complete treatment in eight weeks.

This decision is based on results from a Phase 3 study, which showed the therapy to be safe and effective for acute cases. Mavyret was initially approved in 2017 for newly diagnosed adult Hepatitis C patients.

AbbVie Inc. (NYSE:ABBV) is an international biopharmaceutical firm dedicated to creating and providing advanced treatments for challenging health conditions. The company concentrates on key areas such as immunology, cancer, neuroscience, eye care, and aesthetics. Its goal is to improve lives by researching, developing, and offering new therapies that address serious medical needs that currently lack effective solutions.